Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion

2021/03/09 by Suchit Jhunjhunwala, Christian Hammer, Lélia Delamarre · 21 citations
Immunology and Microbiology · Medicine · #CAR-T cell therapy research #Immune Cell Function and Interaction #Immunotherapy and Immune Responses

paper · doi:10.1038/s41568-021-00339-z

crossref issued 2021/03/09 · crossref published 2021/03/09 · crossref published-online 2021/03/09 · openalex publication_date 2021/03/09 · crossref created 2021/03/09 · crossref published-print 2021/05/01 · crossref deposited 2023/01/29 · openalex created_date 2025/10/10 · crossref indexed 2026/07/30 · openalex updated_date 2026/08/04

Citations

• Zooming into the binding groove of HLA molecules: which positions and which substitutions change peptide binding most?
• NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
• NK cells for cancer immunotherapy
• A conserved dendritic-cell regulatory program limits antitumour immunity
• A guide to cancer immunotherapy: from T cell basic science to clinical practice
• Macrophage targeting in cancer
• An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
• TIGIT in cancer immunotherapy

Cited by

• Tumor-associated neutrophils attenuate the immunosensitivity of hepatocellular carcinoma
• The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
• Neoantigens: promising targets for cancer therapy
• Multiomics Reveals NDRG1-Driven Oral Squamous Cell Carcinoma Progression: Competitive Endogenous RNAs Regulation and Proangiogenic Microenvironment Remodelling
• Molecular determinants of immunogenic cell death elicited by radiation therapy
• A Versatile Polymer‐Based In Situ Nanovaccine to Boost Cancer Immunotherapy
• Cancer epitope prediction tools and analysis pipelines in CEDAR
• Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients
• Intratumoural vaccination via checkpoint degradation-coupled antigen presentation
• Dendritic cell subsets in cancer immunity and tumor antigen sensing
• Reprogramming the tumor microenvironment: synergistic mechanisms of antibody–drug conjugates and immune checkpoint inhibitors
• The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer
• Essential role of NLRC5 in cancer immune surveillance and cancer immunoediting
• A guide to antigen processing and presentation
• Cancer vaccines as promising immuno-therapeutics: platforms and current progress
• The paradoxical role of radiation‐induced cGAS–STING signalling network in tumour immunity
• LSMTCR: A Scalable Multi-Architecture Model for Epitope-Specific T Cell Receptor de novo Design
• HLA-E as an Emerging Checkpoint and Biomarker in Personalized Cancer Immunotherapy
• Rational design of polymer-based mRNA delivery systems for cancer treatment
• Modulation of the Tumor-Associated Immuno-Environment by Non-Invasive Physical Plasma
• Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming